Navigation Links
New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO

nce to imatinib meylate.

Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on Sutent.

Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed. Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure.

Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy. CBCs with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with Sutent.

The most common adverse reactions are fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspensia, abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skin discoloration, altered taste, anorexia and bleeding.

For more information on Sutent and Pfizer Oncology please visit www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as of May 29, 2007. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about various products in development, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such products in development as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
5. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
8. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
9. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
10. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
11. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting

Post Your Comments:
(Date:12/4/2009)... , BILLERICA, Mass., Dec. 4 /PRNewswire-...wned subsidiary of Volcano Corporation (Nasdaq: V... successful testing of a novel integrated light so... this proprietary optical engine design raises the...mitations of laser-based designs for swept source ...
(Date:12/4/2009)... , TARRYTOWN, N.Y., Dec. 4 /PRNewswire/ ...rand prize winners of Bayer,s "Express Your Simple... Brothers, selected the winning video entries subm...untry. The grand prize is an in-person meeting tod... diabetes like Nick, are: Caleb, age 6, from Danbu...
(Date:12/4/2009)... , WILMINGTON, Del., Dec. 4 /PRNewswire-Fir...ced that the US Food and Drug Administration (FDA)...pine fumarate) Extended Release Tablets as adjunct...s with Major Depressive Disorder (MDD). SEROQUEL X...the FDA to treat both major depressive disorder as...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results 13409 1Micromet Inc Reports Second Quarter 2009 Financial Results 53819 1Micromet Inc Reports Second Quarter 2009 Financial Results 53819 2Micromet Inc Reports Second Quarter 2009 Financial Results 53819 3Micromet Inc Reports Second Quarter 2009 Financial Results 53819 4Micromet Inc Reports Second Quarter 2009 Financial Results 53819 5Micromet Inc Reports Second Quarter 2009 Financial Results 53819 6Micromet Inc Reports Second Quarter 2009 Financial Results 53819 7Micromet Inc Reports Second Quarter 2009 Financial Results 53819 8Micromet Inc Reports Second Quarter 2009 Financial Results 53819 9Micromet Inc Reports Second Quarter 2009 Financial Results 53819 10Micromet Inc Reports Second Quarter 2009 Financial Results 53819 11Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 1Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 2Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 3Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 4Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 5Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 6Repligen Reports First Quarter Fiscal Year 2010 Financial Results 13408 7
...ntisense Drug Targeting Glucagon Receptor for Trea..., CARLSBAD, Calif., Oct. 2 Isis,Pharmaceuticals,...ed $5,million from Ortho-McNeil, Inc. (OMI), a Joh...velopment milestone of initializing the Phase 1,cl...tween Isis and OMI, announced on September 13,2007...
...ority Studies versus Hepsera(R) in Patients with C...Studies will also Assess Clevudine,s Sustained Vir... HBV-, PRINCETON, N.J., Oct. 1 Pharmasset...ase 3 registration clinical trials,of clevudine fo...,infection. Clevudine is an oral, once-daily pyrim...
Other Medicine Technology:Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 2Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 3Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 3Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 4Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 5
(Date:12/4/2009)...wcasing Innovative Health Product in Scottsdale ,...-- A valley inventor garnering national attention ...weight, prevent disease, restore health, improve m...product at Saturday’s Technology Fair locate... has been featured on major television networks ac...
(Date:12/4/2009)...ewswire/ -- As Congress prepares to vote on a heal...C) today announced an eight week campaign to call ...ousehold on provisions of the Senate health care b...igher taxes, and government-run health care, or th...opposition to the so-called health care reform wil...
(Date:12/4/2009)...ewswire/ -- Farmers Insurance Missouri State Execu...ndy Cole, and Brad Ballard, the CEO and creator of...mers called FireFacts , will conduct a childr...ber 9. ,, (Logo: http://www.newscom.com/cgi...ire safety comes following a tragic fire that took...
(Date:12/4/2009)...al of Neurosurgery: Pediatrics finds that operati...ma, or JPA, tumors in the thalamus of the brain ca...TI. The sensitivity of DTI imaging allows for the.... This information can maximize the potential of ...e to the fiber bundles that are directly related t...
(Date:12/4/2009)...ng manufacturer of over-the-counter topical cream ...rs’ quality of life, today announced that it...edical Association (APMA) Seal of Approval for its... (PRWEB) December 4, 2009 ...e-counter topical cream and first aid products des...
Breaking Medicine News(10 mins):Health News:Valley Health Invention Making National Splash Showcased at Scottsdale Civic Center Gallery 2Health News:FRC Announces Campaign to Call Every Louisiana Household, Urging Opposition to Health Care Takeover 2Health News:Missouri Safety Day at the Capitol 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 3Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 4
...tic manipulation poses, study finds , , TH...ve converted adult cells into embryonic-like stem ...etic manipulation. , Gene manipulation is an older...ally altering them could lead to the development o...
...nerve damage while performing a robotic assisted l...om becoming impotent, according to a study perform...A. , Preoperative MR was used to evaluate 38 neu... Timothy McClure, MD, lead author of the study. "1...
...redict, with a high degree of confidence, whether ...oscopy or removed through polypectomy, according t... School of Medicine and Public Health in Madison, ...p is found with CT colonography, a corresponding p...
..., which usually indicates prior exposure to tuberc...t typically includes a frontal and lateral view. T...al radiation dose during screening, is not necessa...taken in 857 patients with positive PPD (tuberculo...
... following 62-cent increase on cigarettes , , MIN...e on cigarettes has a lot of Minnesotans trying to...oking program provided by ClearWay Minnesota(SM), ...h Insurance Program (SCHIP). , , (Logo: http://...
... 10 Seconds to Care: Help and Hope for Busy Clinic...ishing program of the American College of Physicia...and advice about the healing power of compassionat...and other health care professionals, the timing fo...
Other Medicine News:Health News:Scientists Find New Way to Create Stem Cells 2Health News:Minnesota Smokers Turning to QUITPLAN(R) Services After Cigarette Tax Hike 2Health News:Minnesota Smokers Turning to QUITPLAN(R) Services After Cigarette Tax Hike 3Health News:'Only 10 Seconds to Care' by Dr. Wendy S. Harpham helps heal clinician-patient bonds 2
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: